Total Payments
$3.0M
2024 Payments
$614,513
Companies
61
Transactions
3,448
Payment Breakdown by Category
Other$1.9M (63.8%)
Travel$446,626 (15.1%)
Consulting$379,214 (12.8%)
Research$130,965 (4.4%)
Food & Beverage$105,956 (3.6%)
Education$9,388 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.6M | 562 | 54.7% |
| Travel and Lodging | $446,626 | 970 | 15.1% |
| Consulting Fee | $379,214 | 142 | 12.8% |
| Honoraria | $264,526 | 105 | 8.9% |
| Unspecified | $130,965 | 30 | 4.4% |
| Food and Beverage | $105,956 | 1,628 | 3.6% |
| Education | $9,388 | 9 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,000 | 1 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,980 | 1 | 0.1% |
Payments by Type
General
$2.8M
3,418 transactions
Research
$130,965
30 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $491,115 | 411 | $0 (2024) |
| GlaxoSmithKline, LLC. | $432,688 | 437 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $419,017 | 470 | $0 (2024) |
| Grifols USA, LLC | $189,387 | 163 | $0 (2024) |
| ABBVIE INC. | $179,153 | 170 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $149,072 | 182 | $0 (2024) |
| CSL Behring | $128,715 | 196 | $0 (2024) |
| PFIZER INC. | $124,335 | 155 | $0 (2024) |
| Horizon Therapeutics plc | $100,700 | 90 | $0 (2023) |
| BioCryst US Sales Co., LLC | $89,260 | 89 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $614,513 | 561 | GENZYME CORPORATION ($157,497) |
| 2023 | $781,559 | 776 | GENZYME CORPORATION ($143,036) |
| 2022 | $647,483 | 733 | GENZYME CORPORATION ($150,533) |
| 2021 | $341,841 | 404 | GlaxoSmithKline, LLC. ($113,093) |
| 2020 | $114,666 | 168 | PFIZER INC. ($17,794) |
| 2019 | $169,704 | 287 | Shire North American Group Inc ($41,534) |
| 2018 | $138,693 | 260 | CSL Behring ($53,013) |
| 2017 | $156,460 | 259 | CSL Behring ($54,737) |
All Payment Transactions
3,448 individual payment records from CMS Open Payments — Page 1 of 138
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $139.83 | General |
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $784.88 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $500.95 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $373.13 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $255.63 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $238.25 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $236.17 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $45.23 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $27.47 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.43 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $0.97 | General |
| Category: Dermatology | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $5,450.00 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $728.63 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $262.20 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $218.41 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $171.46 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $24.08 | General |
| 12/12/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | In-kind items and services | $1,517.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Amgen Inc. | ACTIMMUNE (Biological) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Bone/Inflammation/Rare Disease | ||||||
| 12/12/2024 | Amgen Inc. | ACTIMMUNE (Biological) | Travel and Lodging | Cash or cash equivalent | $33.15 | General |
| Category: Bone/Inflammation/Rare Disease | ||||||
| 12/10/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,810.00 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | Blueprint Medicines Corporation | — | Food and Beverage | Cash or cash equivalent | $112.81 | General |
| 12/05/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CHARACTERIZATION OF UNMET NEED FOR TARGETED PRECISION MEDICATION IN ATOPIC DERMATITIS DUE TO INADEQUATE OR POOR RESPONSE TO DUPILUMAB | LEO Pharma Inc. | $45,000 | 2 |
| SCIG03 | Bio Products Laboratory, Inc. | $19,264 | 1 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $10,210 | 13 |
| CRISABOROLE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,010 | 5 |
| SAFETY PROFILE OF XOLAIR IN THE POST-MARKETING SETTING A SUBANALYSIS OF THE PROSPERO STUDY, A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF XOLAIR IN SUBJECTS WITH MODERATE TO SEVERE PERSISTENT ASTHMA WHO ARE INADEQUATELY CONTROLLED WITH HIGH-DOSE INHALED CORTICOSTEROIDS AND LONG-ACTING BETA-AGONISTS EXTRA | F. Hoffmann-La Roche AG | $4,646 | 1 |
| SAFETY PROFILE OF XOLAIR IN THE POST-MARKETING SETTING A SUBANALYSIS OF THE PROSPERO STUDY, A phase IIIb multicenter, randomized, double-blind, placebo-controlled study of Xolair in subjects with moderate to severe persistent asthma who are inadequately controlled with high-dose inhaled corticosteroids and long-acting beta-agonists EXTRA | F. Hoffmann-La Roche AG | $1,714 | 1 |
| A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | SANOFI-AVENTIS U.S. LLC | $1,530 | 3 |
| A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | GENZYME CORPORATION | $1,250 | 1 |
| CIBINQO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | GENZYME CORPORATION | $500.00 | 1 |
About Dr. Bob Geng, M.D
Dr. Bob Geng, M.D is a Internal Medicine healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2009. The National Provider Identifier (NPI) number assigned to this provider is 1356570758.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bob Geng, M.D has received a total of $3.0M in payments from pharmaceutical and medical device companies, with $614,513 received in 2024. These payments were reported across 3,448 transactions from 61 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.6M).
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Allergy & Immunology
- Location San Diego, CA
- Active Since 07/07/2009
- Last Updated 02/06/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1356570758
Products in Payments
- DUPIXENT (Biological) $785,492
- NUCALA (Biological) $432,179
- Xembify (Biological) $191,140
- RINVOQ (Biological) $179,051
- ACTIMMUNE (Drug) $136,658
- Hizentra (Biological) $75,929
- ORLADEYO (Drug) $67,878
- CIBINQO (Drug) $66,589
- HYQVIA (Biological) $58,372
- CUVITRU (Biological) $57,644
- CINRYZE (Drug) $46,508
- ADBRY (Biological) $46,095
- Haegarda (Biological) $45,433
- JOENJA (Drug) $39,197
- DUPIXENT (Drug) $38,913
- Xhance (Drug) $26,894
- EUCRISA (Drug) $25,842
- Orladeyo (Drug) $21,007
- SUBGAM VF (Biological) $19,264
- OPZELURA (Drug) $19,194
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Diego
Dr. Hatim Husain, Md, MD
Internal Medicine — Payments: $1.9M
Internal Medicine $1.9M
Dr. Steven Edelman, M.d, M.D
Internal Medicine — Payments: $1.3M
Internal Medicine $1.3M
Dr. Gary Firestein, M.d, M.D
Internal Medicine — Payments: $902,808
Internal Medicine $902,808
Dr. Adam Zweig, Md, MD
Internal Medicine — Payments: $385,670
Internal Medicine $385,670
Dr. James Breitmeyer
Internal Medicine — Payments: $362,929
Internal Medicine $362,929
Dr. Bernard Michlin, M.d, M.D
Internal Medicine — Payments: $297,383
Internal Medicine $297,383